Novel targets for detection of cancer and their modulation by chemopreventive natural compounds

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 1, 2012, Pages 410-425

  Ahmad, Aamir ^a   Sakr, Wael A ^a   Rahman, K M Wahidur ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3,3' diindolylmethane; Chemoprevention; Curcumin; CXCR4; DIM; EGCG; EMT; Epigallocatechin 3 Gallate; FoxM1; Genistein; Indole 3 carbinol (I3C); miRNAs; Notch; Resveratrol; Review; Shh; Sonic Hedgehog; Survivin; uPA uPAR; Wnt

Indexed keywords

3 HYDROXYFLAVONE; 3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; APIGENIN; BETULIN; CURCUMIN; DEGUELIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; DOCETAXEL; EPIGALLOCATECHIN GALLATE; FUCOXANTHIN; GARLIC EXTRACT; GENISTEIN; GINGEROL; MASLINIC ACID; NAPHTHOQUINONE; NATURAL PRODUCT; PLUMBAGIN; POLYPHENOL; PSORALIDIN; QUERCETIN; RESVERATROL; SESAMIN; SILIBININ; SMALL INTERFERING RNA; THIOSTREPTON; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL PRODUCT; PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MODEL; CANCER PREVENTION; CELL CYCLE ARREST; CHEMOSENSITIZATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; MOLECULARLY TARGETED THERAPY; MOUTH CANCER; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; DRUG EFFECT; METABOLISM; NEOPLASM;

ERINACEIDAE;

ANTICARCINOGENIC AGENTS; BIOLOGICAL AGENTS; HUMANS; NEOPLASMS; PROTEINS;

EID: 84860878606     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/388     Document Type: Review

References (215)

1. F. H. Sarkar and Y.Li: Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat.Rev. 35, 597-607 (2009)
2. G. L. Russo: Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem.Pharmacol. 74, 533-544 (2007)
3. KM Wahidur Rahman: Mechanistic role of indole-3-carbinol in cancer prevention and therapy. In: Cancer: Disease Progression and Chemoprevention. Eds: Takuji Tanaka, Research Signpost, India (2007)
4. F. H. Sarkar, Y.Li, Z.Wang, and D.Kong: Cellular signaling perturbation by natural products. Cell Signal. 21, 1541-1547 (2009)
5. G. E. Stillfried, D.N.Saunders, and M.Ranson: Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res. 9, R14 (2007)
6. J. S. Rao: Molecular mechanisms of glioma invasiveness: the role of proteases. Nat.Rev.Cancer 3, 489-501 (2003)
7. K. Dass, A.Ahmad, A.S.Azmi, S.H.Sarkar, and F.H.Sarkar: Evolving role of uPA/uPAR system in human cancers. Cancer Treat.Rev. 34, 122-136 (2008)
8. J. L. Fisher, P.S.Mackie, M.L.Howard, H.Zhou, and P.F.Choong: The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin.Cancer Res. 7, 1654-1660 (2001)
9. R. Swiercz, J.D.Wolfe, A.Zaher, and J.Jankun: Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin.Cancer Res. 4, 869-877 (1998)
10. V. Pillay, C.R.Dass, and P.F.Choong: The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25, 33-39 (2007)
11. K. Ishii, S.Usui, Y.Sugimura, H.Yamamoto, K.Yoshikawa, and K.Hiran: Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol.Pharm.Bull. 24, 188-190 (2001)
12. H. Kobayashi, Y.Fukuda, R.Yoshida, Y.Kanada, S.Nishiyama, M.Suzuki, N.Kanayama, and T.Terao: Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model. Int.J.Cancer 112, 519-524 (2004)
13. H. Kobayashi, R.Yoshida, Y.Kanada, Y.Fukuda, T.Yagyu, K.Inagaki, T.Kondo, N.Kurita, M.Suzuki, N.Kanayama, and T.Terao: Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model. J.Cancer Res.Clin.Oncol. 131, 527-538 (2005)
14. N. H. Chen, J.W.Liu, and J.J.Zhong: Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression. Pharmacol.Rep. 62, 150-163 (2010)
15. C. J. Weng and G.C.Yen: The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin.Exp.Metastasis 27, 361-369 (2010)
16. B. B. Aggarwal, A.Kumar, and A.C.Bharti: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23, 363-398 (2003)
17. S. Yodkeeree, W.Chaiwangyen, S.Garbisa, and P.Limtrakul: Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. J.Nutr.Biochem. 20, 87-95 (2009)
18. S. Yodkeeree, C.Ampasavate, B.Sung, B.B.Aggarwal, and P.Limtrakul: Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human breast cancer cell line. Eur.J.Pharmacol. 627, 8-15 (2010)
19. M. H. Kim: Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J.Cell Biochem. 89, 529-538 (2003)
20. Y. C. Ho, S.F.Yang, C.Y.Peng, M.Y.Chou, and Y.C.Chang: Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator. J.Oral Pathol.Med. 36, 588-593 (2007)
21. Y. Li and F.H.Sarkar: Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett. 186, 157-164 (2002)
22. D. Kong, Y.Li, Z.Wang, S.Banerjee, and F.H.Sarkar: Inhibition of angiogenesis and invasion by 3,3′- diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 67, 3310-3319 (2007)
23. A. Ahmad, D.Kong, S.H.Sarkar, Z.Wang, S.Banerjee, and F.H.Sarkar: Inactivation of uPA and its receptor uPAR by 3,3′- diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J.Cell Biochem. 107, 516-527 (2009)
24. K. M. Rahman, S.Ali, A.Aboukameel, S.H.Sarkar, Z.Wang, P.A.Philip, W.A.Sakr, and A.Raz: Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol.Cancer Ther. 6, 2757-2765 (2007)
25. Z. Wang, B.W.Yu, K.M.Rahman, F.Ahmad, and F.H.Sarkar: Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip. Mol.Cancer Ther. 7, 341-349 (2008)
26. K. W. Rahman and F.H.Sarkar: Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'- diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 65, 364-371 (2005)
27. A. Ahmad, D.Kong, Z.Wang, S.H.Sarkar, S.Banerjee, and F.H.Sarkar: Down-regulation of uPA and uPAR by 3,3'- diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J.Cell Biochem. 108, 916-925 (2009)
28. M. acour-Larose, T.M.Hoang, and A.Molla: Survivin, the starlet of the passenger-protein complex : check-up for its tenth anniversary. Med.Sci. (Paris) 24, 828-832 (2008)
29. M. Romagnoli, C.Seveno, R.Bataille, and S.Barille-Nion: (Survivin in cancerology : molecular aspects and therapeutic applications). Med.Sci. (Paris) 24, 821-827 (2008)
30. A. C. Mita, M.M.Mita, S.T.Nawrocki, and F.J.Giles: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin.Cancer Res. 14, 5000-5005 (2008)
31. D. C. Altieri: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8, 61-70 (2008)
32. H. Yamamoto, C.Y.Ngan, and M.Monden: Cancer cells survive with survivin. Cancer Sci. 99, 1709-1714 (2008)
33. M. H. Andersen, I.M.Svane, J.C.Becker, and P.T.Straten: The universal character of the tumor-associated antigen survivin. Clin.Cancer Res. 13, 5991-5994 (2007)
34. N. A. Aqui and R.H.Vonderheide: Survivin as a universal tumor antigen for novel cancer immunotherapy: functions of a killer clone. Cancer Biol.Ther. 7, 1888-1889 (2008)
35. M. Guha and D.C.Altieri: Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8, 2708-2710 (2009)
36. M. Pennati, M.Folini, and N.Zaffaroni: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28, 1133-1139 (2007)
37. M. Pennati, M.Folini, and N.Zaffaroni: Targeting survivin in cancer therapy. Expert.Opin.Ther.Targets. 12, 463-476 (2008)
38. A. Ahmad, W.A.Sakr, and K.M.Rahman: Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr.Drug Targets. 11, 652-666 (2010)
39. K. M. Rahman, O.Aranha, A.Glazyrin, S.R.Chinni, and F.H.Sarkar: Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene 19, 5764-5771 (2000)
40. K. M. Rahman, O.Aranha, and F.H.Sarkar: Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr.Cancer 45, 101-112 (2003)
41. K. M. Rahman, Y.Li, and F.H.Sarkar: Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr.Cancer 48, 84-94 (2004)
42. K. M. Rahman, F.H.Sarkar, S.Banerjee, Z.Wang, D.J.Liao, X.Hong, and N.H.Sarkar: Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol.Cancer Ther. 5, 2747-2756 (2006)
43. Y. Takada, M.Andreeff, and B.B.Aggarwal: Indole-3- carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaBregulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 106, 641-649 (2005)
44. A. Ahmad, A.S.Farhan, S.Singh, and S.M.Hadi: DNA breakage by resveratrol and Cu (II): reaction mechanism and bacteriophage inactivation. Cancer Lett. 154, 29-37 (2000)
45. A. Ahmad, F.A.Syed, S.Singh, and S.M.Hadi: Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. Toxicol.Lett. 159, 1-12 (2005)
46. M. H. Aziz, F.Afaq, and N.Ahmad: Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in survivin. Photochem.Photobiol. 81, 25-31 (2005)
47. M. H. Aziz, S.Reagan-Shaw, J.Wu, B.J.Longley, and N.Ahmad: Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J. 19, 1193-1195 (2005)
48. Y. Hu, S.Rahlfs, V.Mersch-Sundermann, and K.Becker: Resveratrol modulates mRNA transcripts of genes related to redox metabolism and cell proliferation in non-small-cell lung carcinoma cells. Biol.Chem. 388, 207-219 (2007)
49. S. Shankar, G.Singh, and R.K.Srivastava: Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci. 12, 4839-4854 (2007)
50. S. Shankar, I.Siddiqui, and R.K.Srivastava: Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol.Cell Biochem. 304, 273-285 (2007)
51. P. Roy, N.Kalra, S.Prasad, J.George, and Y.Shukla: Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm.Res. 26, 211-217 (2009)
52. S. Fulda and K.M.Debatin: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 64, 337-346 (2004)
53. S. Fulda and K.M.Debatin: Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur.J.Cancer 41, 786-798 (2005)
54. W. Chen, X.Wang, J.Zhuang, L.Zhang, and Y.Lin: Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 28, 2114-2121 (2007)
55. Y. G. Son, E.H.Kim, J.Y.Kim, S.U.Kim, T.K.Kwon, A.R.Yoon, C.O.Yun, and K.S.Choi: Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res. 67, 8274-8284 (2007)
56. R. P. Singh, G.Deep, M.J.Blouin, M.N.Pollak, and R.Agarwal: Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28, 2567-2574 (2007)
57. L. Li, Y.Gao, L.Zhang, J.Zeng, D.He, and Y.Sun: Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett. 272, 61-69 (2008)
58. A. Tyagi, K.Raina, R.P.Singh, M.Gu, C.Agarwal, G.Harrison, L.M.Glode, and R.Agarwal: Chemopreventive effects of silymarin and silibinin on N-butyl-N- (4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol.Cancer Ther. 6, 3248-3255 (2007)
59. K. W. Rahman, Y.Li, Z.Wang, S.H.Sarkar, and F.H.Sarkar: Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res. 66, 4952-4960 (2006)
60. K. M. Rahman and F.H.Sarkar: Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in normal and malignant mammary epithelial cells. J Steroid Biochem.Mol.Biol. 80, 191-201 (2002)
61. N. McLaughlin, B.Annabi, M.Bouzeghrane, A.Temme, J.P.Bahary, R.Moumdjian, and R.Beliveau: The Survivinmediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate. Brain Res. 1071, 1-9 (2006)
62. R. P. Singh and R.Agarwal: Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr.Drug Targets. 7, 345-354 (2006)
63. A. Magalska, M.Sliwinska, J.Szczepanowska, S.Salvioli, C.Franceschi, and E.Sikora: Resistance to apoptosis of HCW-2 cells can be overcome by curcuminor vincristine-induced mitotic catastrophe. Int.J.Cancer 119, 1811-1818 (2006)
64. S. Fulda and K.M.Debatin: Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23, 6702-6711 (2004)
65. R. Dell'Eva, C.Ambrosini, S.Minghelli, D.M.Noonan, A.Albini, and N.Ferrari: The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis 28, 404-413 (2007)
66. X. H. Peng, P.Karna, R.M.O'Regan, X.Liu, R.Naithani, R.M.Moriarty, W.C.Wood, H.Y.Lee, and L.Yang: Downregulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol.Pharmacol. 71, 101-111 (2007)
67. S. Chintharlapalli, S.Papineni, S.K.Ramaiah, and S.Safe: Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 67, 2816-2823 (2007)
68. K. M. Rahman, S.Banerjee, S.Ali, A.Ahmad, Z.Wang, D.Kong, and W.A.Sakr: 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res. 69, 4468-4475 (2009)
69. B. Tian, Z.Wang, Y.Zhao, D.Wang, Y.Li, L.Ma, X.Li, J.Li, N.Xiao, J.Tian, and R.Rodriguez: Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett. 264, 299-308 (2008)
70. P. C. Leow, Q.Tian, Z.Y.Ong, Z.Yang, and P.L.Ee: Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs 28, 766-782 (2010)
71. M. K. Pandey, B.Sung, A.B.Kunnumakkara, G.Sethi, M.M.Chaturvedi, and B.B.Aggarwal: Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 68, 5370-5379 (2008)
72. S. M. Shaarawy, A.A.Tohamy, S.M.Elgendy, Z.Y.Elmageed, A.Bahnasy, M.S.Mohamed, E.Kandil, and K.Matrougui: Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity. Int.J.Biol.Sci. 5, 549-557 (2009)
73. R. Gomathinayagam, S.Sowmyalakshmi, F.Mardhatillah, R.Kumar, M.A.Akbarsha, and C.Damodaran: Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res. 28, 785-792 (2008)
74. C. Ishikawa, S.Tafuku, T.Kadekaru, S.Sawada, M.Tomita, T.Okudaira, T.Nakazato, T.Toda, J.N.Uchihara, N.Taira, K.Ohshiro, T.Yasumoto, T.Ohta, and N.Mori: Anti-adult Tcell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Int.J.Cancer 123, 2702-2712 (2008)
75. R. Kumar, S.Srinivasan, S.Koduru, P.Pahari, J.Rohr, N.Kyprianou, and C.Damodaran: Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev.Res. (Phila Pa) 2, 234-243 (2009)
76. N. Nigam, J.George, S.Srivastava, P.Roy, K.Bhui, M.Singh, and Y.Shukla: Induction of apoptosis by (6)-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B (a)P-induced mouse skin tumorigenesis. Cancer Chemother.Pharmacol. 65, 687-696 (2010)
77. P. Roy, N.Nigam, J.George, S.Srivastava, and Y.Shukla: Induction of apoptosis by tea polyphenols mediated through mitochondrial cell death pathway in mouse skin tumors. Cancer Biol.Ther. 8, 1281-1287 (2009)
78. S. Banerjee, Z.Wang, D.Kong, and F.H.Sarkar: 3,3'- Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 69, 5592-5600 (2009)
79. Z. Wang, A.Ahmad, S.Banerjee, A.Azmi, D.Kong, Y.Li, and F.H.Sarkar: FoxM1 is a Novel Target of a Natural Agent in Pancreatic Cancer. Pharm.Res. 27, 1159-1168 (2010)
80. C. Li, Z.Yang, C.Zhai, W.Qiu, D.Li, Z.Yi, L.Wang, J.Tang, M.Qian, J.Luo, and M.Liu: Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway. Mol.Cancer 9, 73 (2010)
81. P. Siripong, C.Hahnvajanawong, J.Yahuafai, S.Piyaviriyakul, K.Kanokmedhakul, N.Kongkathip, S.Ruchirawat, and N.Oku: Induction of apoptosis by rhinacanthone isolated from Rhinacanthus nasutus roots in human cervical carcinoma cells. Biol.Pharm.Bull. 32, 1251-1260 (2009)
82. K. B. Harikumar, B.Sung, S.T.Tharakan, M.K.Pandey, B.Joy, S.Guha, S.Krishnan, and B.B.Aggarwal: Sesamin Manifests Chemopreventive Effects through the Suppression of NF-kappa BRegulated Cell Survival, Proliferation, Invasion, and Angiogenic Gene Products. Mol.Cancer Res. 8, 751-761 (2010)
83. N. Bhatnagar, X.Li, Y.Chen, X.Zhou, S.H.Garrett, and B.Guo: 3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through downregulation of survivin. Cancer Prev.Res. (Phila Pa) 2, 581-589 (2009)
84. Y. Nakamura, S.Yogosawa, Y.Izutani, H.Watanabe, E.Otsuji, and T.Sakai: A combination of indol-3- carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol.Cancer 8, 100 (2009)
85. S. Sreevalsan, I.Jutooru, G.Chadalapaka, M.Walker, and S.Safe: 1,1-Bis (3'-indolyl)-1- (pbromophenyl) methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cells. Int.J.Oncol. 35, 1191-1199 (2009)
86. H. Ye, A.X.Holterman, K.W.Yoo, R.R.Franks, and R.H.Costa: Premature expression of the winged helix transcription factor HFH-11B in regenerating mouse liver accelerates hepatocyte entry into S phase. Mol.Cell Biol. 19, 8570-8580 (1999)
87. X. Wang, H.Kiyokawa, M.B.Dennewitz, and R.H.Costa: The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc.Natl.Acad.Sci.U.S.A 99, 16881-16886 (2002)
88. D. R. Wonsey and M.T.Follettie: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 65, 5181-5189 (2005)
89. M. Katoh and M.Katoh: Human FOX gene family (Review). Int.J.Oncol. 25, 1495-1500 (2004)
90. Z. Wang, S.Banerjee, D.Kong, Y.Li, and F.H.Sarkar: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 67, 8293-8300 (2007)
91. B. Dai, S.H.Kang, W.Gong, M.Liu, K.D.Aldape, R.Sawaya, and S.Huang: Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 26, 6212-6219 (2007)
92. M. Halasi and A.L.Gartel: A novel mode of FoxM1 regulation: Positive auto-regulatory loop. Cell Cycle 8, 1966-1967 (2009)
93. T. V. Kalin, I.C.Wang, T.J.Ackerson, M.L.Major, C.J.Detrisac, V.V.Kalinichenko, A.Lyubimov, and R.H.Costa: Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66, 1712-1720 (2006)
94. S. K. Radhakrishnan, U.G.Bhat, D.E.Hughes, I.C.Wang, R.H.Costa, and A.L.Gartel: Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 66, 9731-9735 (2006)
95. Z. Wang, A.Ahmad, Y.Li, S.Banerjee, D.Kong, and F.H.Sarkar: Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat.Rev. 36, 151-156 (2010)
96. G. R. Adami and H.Ye: Future roles for FoxM1 inhibitors in cancer treatments. Future.Oncol. 3, 1-3 (2007)
97. S. K. Radhakrishnan and A.L.Gartel: FOXM1: the Achilles' heel of cancer?. Nat.Rev.Cancer 8, c1 (2008)
98. V. V. Kalinichenko, M.L.Major, X.Wang, V.Petrovic, J.Kuechle, H.M.Yoder, M.B.Dennewitz, B.Shin, A.Datta, P.Raychaudhuri, and R.H.Costa: Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 18, 830-850 (2004)
99. I. M. Kim, T.Ackerson, S.Ramakrishna, M.Tretiakova, I.C.Wang, T.V.Kalin, M.L.Major, G.A.Gusarova, H.M.Yoder, R.H.Costa, and V.V.Kalinichenko: The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 66, 2153-2161 (2006)
100. M. Liu, B.Dai, S.H.Kang, K.Ban, F.J.Huang, F.F.Lang, K.D.Aldape, T.X.Xie, C.E.Pelloski, K.Xie, R.Sawaya, and S.Huang: FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells 45. Cancer Res. 66, 3593-3602 (2006)
101. Y. Zhang, N.Zhang, B.Dai, M.Liu, R.Sawaya, K.Xie, and S.Huang: FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells 19. Cancer Res. 68, 8733-8742 (2008)
102. D. W. Chan, S.Y.Yu, P.M.Chiu, K.M.Yao, V.W.Liu, A.N.Cheung, and H.Y.Ngan: Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis23. J.Pathol. 215, 245-252 (2008)
103. Q. Li, N.Zhang, Z.Jia, X.Le, B.Dai, D.Wei, S.Huang, D.Tan, and K.Xie: Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression14. Cancer Res. 69, 3501-3509 (2009)
104. I. C. Wang, Y.J.Chen, D.E.Hughes, T.Ackerson, M.L.Major, V.V.Kalinichenko, R.H.Costa, P.Raychaudhuri, A.L.Tyner, and L.F.Lau: FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J.Biol.Chem. 283, 20770-20778 (2008)
105. I. C. Wang, L.Meliton, M.Tretiakova, R.H.Costa, V.V.Kalinichenko, and T.V.Kalin: Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene 27, 4137-4149 (2008)
106. Y. Yoshida, I.C.Wang, H.M.Yoder, N.O.Davidson, and R.H.Costa: The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer 36. Gastroenterology 132, 1420-1431 (2007)
107. J. M. Kwok, S.S.Myatt, C.M.Marson, R.C.Coombes, D.Constantinidou, and E.W.Lam: Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol.Cancer Ther. 7, 2022-2032 (2008)
108. U. B. McGovern, R.E.Francis, B.Peck, S.K.Guest, J.Wang, S.S.Myatt, J.Krol, J.M.Kwok, A.Polychronis, R.C.Coombes, and E.W.Lam: Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol.Cancer Ther. 8, 582-591 (2009)
109. A. Ahmad, Z.Wang, D.Kong, S.Ali, Y.Li, S.Banerjee, R.Ali, and F.H.Sarkar: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res.Treat. 122, 337-346 (2010)
110. S. rtavanis-Tsakonas, K.Matsuno, and M.E.Fortini: Notch signaling. Science 268, 225-232 (1995)
111. S. rtavanis-Tsakonas, M.D.Rand, and R.J.Lake: Notch signaling: cell fate control and signal integration in development. Science 284, 770-776 (1999)
112. F. Radtke and K.Raj: The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat.Rev.Cancer 3, 756-767 (2003)
113. W. R. Gordon, D.Vardar-Ulu, G.Histen, C.Sanchez-Irizarry, J.C.Aster, and S.C.Blacklow: Structural basis for autoinhibition of Notch. Nat.Struct.Mol.Biol. 14, 295-300 (2007)
114. L. W. Ellisen, J.Bird, D.C.West, A.L.Soreng, T.C.Reynolds, S.D.Smith, and J.Sklar: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661 (1991)
115. F. Jundt, I.Anagnostopoulos, R.Forster, S.Mathas, H.Stein, and B.Dorken: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99, 3398-3403 (2002)
116. O. Hopfer, D.Zwahlen, M.F.Fey, and S.Aebi: The Notch pathway in ovarian carcinomas and adenomas. Br.J.Cancer 93, 709-718 (2005)
117. B. W. Purow, R.M.Haque, M.W.Noel, Q.Su, M.J.Burdick, J.Lee, T.Sundaresan, S.Pastorino, J.K.Park, I.Mikolaenko, D.Maric, C.G.Eberhart, and H.A.Fine: Expression of Notch-1 and its ligands, Deltalike-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65, 2353-2363 (2005)
118. Z. Wang, Y.Zhang, S.Banerjee, Y.Li, and F.H.Sarkar: Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106, 2503-2513 (2006)
119. A. O. Rehman and C.Y.Wang: Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol. 16, 293-300 (2006)
120. Z. Wang, Y.Li, S.Banerjee, D.Kong, A.Ahmad, V.Nogueira, N.Hay, and F.H.Sarkar: Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J.Cell Biochem. 109, 726-736 (2010)
121. A. Ahmad, Z.Wang, D.Kong, R.Ali, S.Ali, S.Banerjee, and F.H.Sarkar: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat. (2010)
122. S. Weijzen, P.Rizzo, M.Braid, R.Vaishnav, S.M.Jonkheer, A.Zlobin, B.A.Osborne, S.Gottipati, J.C.Aster, W.C.Hahn, M.Rudolf, K.Siziopikou, W.M.Kast, and L.Miele: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat.Med. 8, 979-986 (2002)
123. S. Stylianou, R.B.Clarke, and K.Brennan: Aberrant activation of notch signaling in human breast cancer. Cancer Res 66, 1517-1525 (2006)
124. C. Hu, A.Dievart, M.Lupien, E.Calvo, G.Tremblay, and P.Jolicoeur: Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am.J.Pathol. 168, 973-990 (2006)
125. K. Politi, N.Feirt, and J.Kitajewski: Notch in mammary gland development and breast cancer. Semin.Cancer Biol. 14, 341-347 (2004)
126. C. Parr, G.Watkins, and W.G.Jiang: The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int.J.Mol.Med. 14, 779-786 (2004)
127. M. Reedijk, S.Odorcic, L.Chang, H.Zhang, N.Miller, D.R.McCready, G.Lockwood, and S.E.Egan: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65, 8530-8537 (2005)
128. R. Callahan and S.E.Egan: Notch signaling in mammary development and oncogenesis. J.Mammary.Gland.Biol.Neoplasia. 9, 145-163 (2004)
129. S. Zang, C.Ji, X.Qu, X.Dong, D.Ma, J.Ye, R.Ma, J.Dai, and D.Guo: A study on Notch signaling in human breast cancer. Neoplasma 54, 304-310 (2007)
130. Z. Wang, S.Desmoulin, S.Banerjee, D.Kong, Y.Li, R.L.Deraniyagala, J.Abbruzzese, and F.H.Sarkar: Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci. 83, 293-300 (2008)
131. Y. Chen, W.Shu, W.Chen, Q.Wu, H.Liu, and G.Cui: Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin.Pharmacol.Toxicol. 101, 427-433 (2007)
132. V. Cecchinato, R.Chiaramonte, M.Nizzardo, B.Cristofaro, A.Basile, G.V.Sherbet, and P.Comi: Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem.Pharmacol. 74, 1568-1574 (2007)
133. Q. Wang, H.Li, N.Liu, X.Y.Chen, M.L.Wu, K.L.Zhang, Q.Y.Kong, and J.Liu: Correlative analyses of notch signaling with resveratrol-induced differentiation and apoptosis of human medulloblastoma cells. Neurosci.Lett. 438, 168-173 (2008)
134. Z. Wang, Y.Zhang, S.Banerjee, Y.Li, and F.H.Sarkar: Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int.J.Cancer 118, 1930-1936 (2006)
135. S. Koduru, R.Kumar, S.Srinivasan, M.B.Evers, and C.Damodaran: Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol.Cancer Ther. 9, 202-210 (2010)
136. J. A. Burger and T.J.Kipps: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761-1767 (2006)
137. R. J. Epstein: The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat.Rev.Cancer 4, 901-909 (2004)
138. K. E. Luker and G.D.Luker: Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 238, 30-41 (2006)
139. M. Arya, H.Ahmed, N.Silhi, M.Williamson, and H.R.Patel: Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour.Biol. 28, 123-131 (2007)
140. A. Zlotnik: New insights on the role of CXCR4 in cancer metastasis. J Pathol. 215, 211-213 (2008)
141. C. C. Schimanski, P.R.Galle, and M.Moehler: Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol. 14, 4721-4724 (2008)
142. C. V. Hinton, S.Avraham, and H.K.Avraham: Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin.Exp.Metastasis 27, 97-105 (2010)
143. J. A. Burger and A.Peled: CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23, 43-52 (2009)
144. S. Gelmini, M.Mangoni, M.Serio, P.Romagnani, and E.Lazzeri: The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J Endocrinol.Invest 31, 809-819 (2008)
145. S. Otsuka and G.Bebb: The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J Thorac.Oncol. 3, 1379-1383 (2008)
146. D. Wong and W.Korz: Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clin.Cancer Res 14, 7975-7980 (2008)
147. B. F. Chong and C.Mohan: Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert.Opin.Ther.Targets. 13, 1147-1153 (2009)
148. A. M. Fulton: The chemokine receptors CXCR4 and CXCR3 in cancer. Curr.Oncol.Rep. 11, 125-131 (2009)
149. E. L. Hsu, N.Chen, A.Westbrook, F.Wang, R.Zhang, R.T.Taylor, and O.Hankinson: CXCR4 and CXCL12 down-regulation: a novel mechanism for the chemoprotection of 3,3'-diindolylmethane for breast and ovarian cancers. Cancer Lett. 265, 113-123 (2008)
150. E. L. Hsu, N.Chen, A.Westbrook, F.Wang, R.Zhang, R.T.Taylor, and O.Hankinson: Modulation of CXCR4, CXCL12, and Tumor Cell Invasion Potential In vitro by Phytochemicals. J.Oncol. 2009, 491985 (2009)
151. J. R. Weng, C.H.Tsai, H.A.Omar, A.M.Sargeant, D.Wang, S.K.Kulp, C.L.Shapiro, and C.S.Chen: OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling. Carcinogenesis 30, 1702-1709 (2009)
152. J. Skommer, D.Wlodkowic, and J.Pelkonen: Geneexpression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp.Hematol. 35, 84-95 (2007)
153. B. E. Bachmeier, I.V.Mohrenz, V.Mirisola, E.Schleicher, F.Romeo, C.Hohneke, M.Jochum, A.G.Nerlich, and U.Pfeffer: Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 29, 779-789 (2008)
154. A. B. Kunnumakkara, P.Diagaradjane, P.Anand, K.B.Harikumar, A.Deorukhkar, J.Gelovani, S.Guha, S.Krishnan, and B.B.Aggarwal: Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int.J Cancer 125, 2187-2197 (2009)
155. W. J. Nelson and R.Nusse: Convergence of Wnt, {beta}-Catenin, and Cadherin Pathways. Science 303, 1483-1487 (2004)
156. R. T. Moon, A.D.Kohn, G.V.De Ferrari, and A.Kaykas: WNT and beta-catenin signalling: diseases and therapies. Nat.Rev.Genet. 5, 691-701 (2004)
157. B. T. MacDonald, K.Tamai, and X.He: Wnt/betacatenin signaling: components, mechanisms, and diseases. Dev.Cell 17, 9-26 (2009)
158. Y. Li, T.Zhang, H.Korkaya, S.Liu, H.F.Lee, B.Newman, Y.Yu, S.G.Clouthier, S.J.Schwartz, M.S.Wicha, and D.Sun: Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin.Cancer Res 16, 2580-2590 (2010)
159. J. Gwak, S.Park, M.Cho, T.Song, S.H.Cha, D.E.Kim, Y.J.Jeon, J.G.Shin, and S.Oh: Polysiphonia japonica extract suppresses the Wnt/beta-catenin pathway in colon cancer cells by activation of NF-kappaB. Int.J.Mol.Med. 17, 1005-1010 (2006)
160. K. Lim, C.Han, L.Xu, K.Isse, A.J.Demetris, and T.Wu: Cyclooxygenase-2- derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res 68, 553-560 (2008)
161. K. Lim, C.Han, Y.Dai, M.Shen, and T.Wu: Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol.Cancer Ther. 8, 3046-3055 (2009)
162. A. K. Joe, H.Liu, M.Suzui, M.E.Vural, D.Xiao, and I.B.Weinstein: Resveratrol induces growth inhibition, Sphase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin.Cancer Res 8, 893-903 (2002)
163. J. Rajakangas, M.Misikangas, E.Paivarinta, and M.Mutanen: Chemoprevention by white currant is mediated by the reduction of nuclear beta-catenin and NF-kappaB levels in Min mice adenomas. Eur.J.Nutr. 47, 115-122 (2008)
164. M. Saleem, I.Murtaza, R.S.Tarapore, Y.Suh, V.M.Adhami, J.J.Johnson, I.A.Siddiqui, N.Khan, M.Asim, B.B.Hafeez, M.T.Shekhani, B.Li, and H.Mukhtar: Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis 30, 808-817 (2009)
165. B. Velmurugan, R.P.Singh, N.Kaul, R.Agarwal, and C.Agarwal: Dietary feeding of grape seed extract prevents intestinal tumorigenesis in APCmin/+ mice. Neoplasia. 12, 95-102 (2010)
166. S. Rajamanickam, B.Velmurugan, M.Kaur, R.P.Singh, and R.Agarwal: Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res 70, 2368-2378 (2010)
167. S. Y. Latifah, N.Armania, T.H.Tze, Y.Azhar, A.H.Nordiana, S.Norazalina, I.Hairuszah, M.Saidi, and I.Maznah: Germinated brown rice (GBR) reduces the incidence of aberrant crypt foci with the involvement of beta-catenin and COX-2 in azoxymethane-induced colon cancer in rats. Nutr.J. 9, 16 (2010)
168. G. Murillo, X.Peng, K.E.Torres, and R.G.Mehta: Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev.Res (Phila Pa) 2, 942-950 (2009)
169. Y. Li, Z.Wang, D.Kong, S.Murthy, Q.P.Dou, S.Sheng, G.P.Reddy, and F.H.Sarkar: Regulation of FOXO3a/betacatenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J.Biol.Chem. 282, 21542-21550 (2007)
170. A. S. Jaiswal, B.P.Marlow, N.Gupta, and S.Narayan: Betacatenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21, 8414-8427 (2002)
171. S. Narayan: Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting betacatenin-mediated transactivation and cell-cell adhesion pathways. J.Mol.Histol. 35, 301-307 (2004)
172. C. P. Prasad, G.Rath, S.Mathur, D.Bhatnagar, and R.Ralhan: Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem.Biol.Interact. 181, 263-271 (2009)
173. M. H. Elamin, Z.Shinwari, S.F.Hendrayani, H.Al-Hindi, E.Al-Shail, Y.Khafaga, A.Al-Kofide, and A.Aboussekhra: Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol.Carcinog. 49, 302-314 (2010)
174. H. Shibata, H.Yamakoshi, A.Sato, H.Ohori, Y.Kakudo, C.Kudo, Y.Takahashi, M.Watanabe, H.Takano, C.Ishioka, T.Noda, and Y.Iwabuchi: Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci. 100, 956-960 (2009)
175. A. Y. Issa, S.R.Volate, S.J.Muga, D.Nitcheva, T.Smith, and M.J.Wargovich: Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model. Carcinogenesis 28, 1978-1984 (2007)
176. M. Shimizu, Y.Shirakami, H.Sakai, S.Adachi, K.Hata, Y.Hirose, H.Tsurumi, T.Tanaka, and H.Moriwaki: (-)- Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev.Res (Phila Pa) 1, 298-304 (2008)
177. R. L. Thangapazham, N.Passi, and R.K.Maheshwari: Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol.Ther. 6, 1938-1943 (2007)
178. P. W. Ingham and A.P.McMahon: Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15, 3059-3087 (2001)
179. B. Z. Stanton and L.F.Peng: Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol.Biosyst. 6, 44-54 (2010)
180. D. M. Stone, M.Hynes, M.Armanini, T.A.Swanson, Q.Gu, R.L.Johnson, M.P.Scott, D.Pennica, A.Goddard, H.Phillips, M.Noll, J.E.Hooper, S.F.de, and A.Rosenthal: The tumoursuppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 384, 129-134 (1996)
181. J. M. Bailey, P.K.Singh, and M.A.Hollingsworth: Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem. 102, 829-839 (2007)
182. M. F. Barginear, M.Leung, and D.R.Budman: The hedgehog pathway as a therapeutic target for treatment of breast cancer. Breast Cancer Res Treat. 116, 239-246 (2009)
183. Y. Katoh and M.Katoh: Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr.Mol.Med 9, 873-886 (2009)
184. L. Yang, G.Xie, Q.Fan, and J.Xie: Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29, 469-481 (2010)
185. A. Slusarz, N.S.Shenouda, M.S.Sakla, S.K.Drenkhahn, A.S.Narula, R.S.MacDonald, C.L.Besch-Williford, and D.B.Lubahn: Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res 70, 3382-3390 (2010)
186. G. Q. Tang, T.Q.Yan, W.Guo, T.T.Ren, C.L.Peng, H.Zhao, X.C.Lu, F.L.Zhao, and X.Han: (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin.Oncol. 136, 1179-1185 (2010)
187. J. J. Christiansen and A.K.Rajasekaran: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis 1. Cancer Res. 66, 8319-8326 (2006)
188. J. P. Thiery: Epithelial-mesenchymal transitions in tumour progression. Nat.Rev.Cancer 2, 442-454 (2002)
189. Z. Wang, Y.Li, and F.H.Sarkar: Signaling mechanism (s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression. Curr.Stem Cell Res Ther. 5, 74-80 (2010)
190. F. H. Sarkar, Y.Li, Z.Wang, and D.Kong: Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 64, 489-500 (2009)
191. S. Ray, N.Chattopadhyay, A.Mitra, M.Siddiqi, and A.Chatterjee: Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J.Environ.Pathol.Toxicol. Oncol. 22, 49-58 (2003)
192. H. W. Chen, J.Y.Lee, J.Y.Huang, C.C.Wang, W.J.Chen, S.F.Su, C.W.Huang, C.C.Ho, J.J.Chen, M.F.Tsai, S.L.Yu, and P.C.Yang: Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 68, 7428-7438 (2008)
193. Z. L. Zhao, Q.F.Li, Y.B.Zheng, L.Y.Chen, S.L.Shi, and G.J.Jing: The aberrant expressions of nuclear matrix proteins during the apoptosis of human osteosarcoma cells. Anat.Rec. (Hoboken.) 293, 813-820 (2010)
194. Q. Meng, I.D.Goldberg, E.M.Rosen, and S.Fan: Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat. 63, 147-152 (2000)
195. K. J. Wu, J.Zeng, G.D.Zhu, L.L.Zhang, D.Zhang, L.Li, J.H.Fan, X.Y.Wang, and D.L.He: Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol.Sin. 30, 1162-1168 (2009)
196. Y. Li, T.G.VandenBoom, D.Kong, Z.Wang, S.Ali, P.A.Philip, and F.H.Sarkar: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69, 6704-6712 (2009)
197. S. K. Shenouda and S.K.Alahari: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 28, 369-378 (2009)
198. G. Ruvkun: The perfect storm of tiny RNAs. Nat.Med. 14, 1041-1045 (2008)
199. C. M. Croce: Causes and consequences of microRNA dysregulation in cancer. Nat.Rev.Genet. 10, 704-714 (2009)
200. J. A. Foekens, A.M.Sieuwerts, M.Smid, M.P.Look, W.de, V, A.W.Boersma, J.G.Klijn, E.A.Wiemer, and J.W.Martens: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc.Natl.Acad.Sci.U.S.A 105, 13021-13026 (2008)
201. L. Ma, J.Teruya-Feldstein, and R.A.Weinberg: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682-688 (2007)
202. P. A. Gregory, A.G.Bert, E.L.Paterson, S.C.Barry, A.Tsykin, G.Farshid, M.A.Vadas, Y.Khew-Goodall, and G.J.Goodall: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 6. Nat.Cell Biol. 10, 593-601 (2008)
203. Y. Li, D.Kong, Z.Wang, and F.H.Sarkar: Regulation of microRNAs by Natural Agents: An Emerging Field in Chemoprevention and Chemotherapy Research. Pharm.Res 27, 1027-1041 (2010)
204. W. J. Lukiw, Y.Zhao, and J.G.Cui: An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J.Biol.Chem. 283, 31315-31322 (2008)
205. W. P. Tsang and T.T.Kwok: Epigallocatechin gallate upregulation of miR-16 and induction of apoptosis in human cancer cells. J.Nutr.Biochem. 21, 140-146 (2010)
206. C. D. Davis and S.A.Ross: Evidence for dietary regulation of microRNA expression in cancer cells. Nutr.Rev. 66, 477-482 (2008)
207. M. Sun, Z.Estrov, Y.Ji, K.R.Coombes, D.H.Harris, and R.Kurzrock: Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol.Cancer Ther. 7, 464-473 (2008)
208. X. Y. Wen, S.Y.Wu, Z.Q.Li, Z.Q.Liu, J.J.Zhang, G.F.Wang, Z.H.Jiang, and S.G.Wu: Ellagitannin (BJA3121), an anti-proliferative natural polyphenol compound, can regulate the expression of MiRNAs in HepG2 cancer cells. Phytother.Res 23, 778-784 (2009)
209. T. Melkamu, X.Zhang, J.Tan, Y.Zeng, and F.Kassie: Alteration of microRNA expression in vinyl carbamateinduced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 31, 252-258 (2010)
210. Y. Li, T.G.VandenBoom, Z.Wang, D.Kong, S.Ali, P.A.Philip, and F.H.Sarkar: miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 70, 1486-1495 (2010)
211. S. Padhye, H.Yang, A.Jamadar, Q.C.Cui, D.Chavan, K.Dominiak, J.McKinney, S.Banerjee, Q.P.Dou, and F.H.Sarkar: New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm.Res 26, 1874-1880 (2009)
212. S. Ali, A.Ahmad, S.Banerjee, S.Padhye, K.Dominiak, J.M.Schaffert, Z.Wang, P.A.Philip, and F.H.Sarkar: Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70, 3606-3617 (2010)
213. S. Padhye, S.Banerjee, D.Chavan, S.Pandye, K.V.Swamy, S.Ali, J.Li, Q.P.Dou, and F.H.Sarkar: Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm.Res 26, 2438-2445 (2009)
214. F. H. Sarkar, Y.Li, Z.Wang, and S.Padhye: Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs. Curr.Pharm.Des 16, 1801-1812 (2010)
215. S. Padhye, D.Chavan, S.Pandey, J.Deshpande, K.V.Swamy, and F.H.Sarkar: Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry. Mini.Rev.Med Chem. 10, 372-387 (2010)